Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Over 2.3 million people have hep C in the United States. The liver disease can be cured—but first, you must know your status.
A distinct set of microbes sets apart people with advanced fibrosis from those with minimal fibrosis.
The profile of chronic liver disease has changed due to obesity trends and advances in the treatment of hepatitis C.
Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.
Primary biliary cholangitis (PBC) is a chronic liver disease resulting from the destruction of the bile ducts in the liver.
A quick overview of our reporting on the 53rd International Liver Congress in Vienna
Among those with primary biliary cholangitis, the investigational drug reduced alkaline phosphatase levels.
In a small ongoing study, the treatment showed an anti-cholestatic effect.
Researchers sought to deduce what drives these symptoms by comparing people with hep C with those who have other liver diseases.
The risk for death from cirrhosis itself is particularly high.
The FDA has approved Intercept Pharmaceuticals’ Ocaliva to treat primary biliary cholangitis, previously known as primary biliary cirrhosis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.